Randle v. SmithKline Beecham Corp.

338 F. Supp. 2d 704, 2004 U.S. Dist. LEXIS 20196, 2004 WL 2240998
CourtDistrict Court, S.D. Mississippi
DecidedSeptember 30, 2004
Docket3:03-cv-00746
StatusPublished
Cited by5 cases

This text of 338 F. Supp. 2d 704 (Randle v. SmithKline Beecham Corp.) is published on Counsel Stack Legal Research, covering District Court, S.D. Mississippi primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Randle v. SmithKline Beecham Corp., 338 F. Supp. 2d 704, 2004 U.S. Dist. LEXIS 20196, 2004 WL 2240998 (S.D. Miss. 2004).

Opinion

OPINION AND ORDER

BARBOUR, District Judge.

Before the Court is Plaintiffs’ Motion to Remand. Having considered the Motion, Response, attachments to each, and supporting and opposing authority, the Court finds that Plaintiffs’ Motion to Remand is not well taken and should be denied.

I. Background and Procedural History

The issue and sub-issues of this case arise out of a personal injury action for uses of the recalled drug, Lotronex® (“Lo-tronex”). All that is necessary for an understanding of this Opinion and Order is a brief recitation of pertinent facts. 1

In their Complaint, Plaintiffs named both diverse and non-diverse Defendants. *706 The first issue in this case involves the named non-diverse Defendants, Amy Adams, Brian Phillips, and Greg Ward. 2 The Complaint alleges these three Defendants (“Sales Defendants”) sold Lotronex, the drug which allegedly caused Plaintiffs’ injuries. These three Sales Defendants, and solely they, destroy complete diversity.

The problem is that Sales Defendants have each provided this Court with affidavits in which they proclaim they neither sold Lotronex, nor worked for the company that sold Lotronex. Those affidavits remain uncontradicted. As a result, Defendants argue that Sales Defendants were improperly joined in this action. 3 Consequently, they argue complete diversity exists and this Court has proper jurisdiction.

The second issue concerns the amount of damages Plaintiffs’ assert in their Complaint. There are thirty-nine Plaintiffs in this action. Plaintiffs purport to limit each Plaintiffs damages to $74,000, although the Complaint and Motion to Remand are less than decipherable as to exactly how this is so. While Plaintiffs purportedly self-impose this ceiling upon recovery, they seek damages, both compensatory and punitive, under numerous theories against numerous corporate and business Defendants. Defendants argue that the number of Plaintiffs, the types of damages sought, and the theories of recovery make it facially apparent that Plaintiffs seek an amount greater than $75,000. Further, Defendants argue that even if it is not facially apparent Plaintiffs seek an amount greater than $75,000, similar drug-litigation cases from around Mississippi demonstrate that Plaintiffs seek such an amount.

II. Introductory Analysis

The issue before the Court is whether the requirements of 28 U.S.C. § 1332 are met, so that this Court can retain jurisdiction. § 1332 provides for diversity jurisdiction in the federal courts, but only when two requirements are met. First, the parties must be citizens of a different states, in that they are completely diverse. Id. Second, the amount in controversy must be greater than $75,000. Id.

Both of those requirements are at issue in this case. First, this Court must an *707 swer whether three particular defendants were improperly joined to destroy complete diversity. Second, this Court must address whether Plaintiffs seek more than $75,000, despite language used in the Complaint which seemingly disavows any attempt to recover more than this amount. The Court addresses these two requirements in chronological order below.

III. Improper Joinder Standard

Under 28 U.S.C. § 1441(a), “any civil action brought in a State court of which the district courts of the United States have original jurisdiction, may be removed ... to the district court of the United States for the district and division embracing the place where such action is pending.” The removing party has the burden of proving that the federal court has jurisdiction to hear the case. Jernigan v. Ashland Oil, Inc., 989 F.2d 812, 815 (5th Cir.1993), ce rt. denied, 510 U.S. 868, 114 S.Ct. 192, 126 L.Ed.2d 150 (1993). In cases in which the removing party alleges diversity of citizenship jurisdiction on the basis of improper joinder, “it has the burden of proving the fraud.” Laughlin, 882 F.2d at 190.

To establish improper joinder, the removing party must prove: “(1) actual fraud in the pleading of jurisdictional facts, or (2) inability of the plaintiff to establish a cause of action against the non-diverse party in state court.” Travis v. Irby, 326 F.3d 644, 647 (5th Cir.2003) (citing Griggs v. State Farm Lloyds, 181 F.3d 694, 698 (5th Cir.1999)).

IV. Analysis — Improper Joinder

The question in this case is whether there is any reasonable basis on which Plaintiffs would be able to establish a cause of action against the Sales Defendants in state court. 4 See Smallwood v. Ill. Central Railroad Co., 385 F.3d 568, 572-73 (2004) (adopting this phrasing of the issue and rejecting all others). The easily reached answer is no.

In Plaintiffs’ Motion to Remand, they make the following generic statement: “Plaintiffs file their Complaint.. .against Brian Phillips and Greg Ward 5 who are pharmaceutical sales representatives and *708 adult resident citizens of the State of Mississippi ... and were at the time of filing the lawsuit, residents of Mississippi. Thus, diversity of jurisdiction does not exist.” See Motion to Remand, ¶ 2, dated June 27, 2003. Plaintiffs proceed to state they “nam[ed] two responsible non-diverse parties, namely Brian Phillips and Greg Ward.” Id. at ¶ 10 (emphasis added).

The problem for Plaintiffs is that Defendants, in their Response in Opposition to Plaintiffs’ Motion to Remand, correctly state that “[t]he uncontradicted affidavits of Phillips, Ward, and Adams [Sales Defendants] establish that they were never employed by Glaxo Wellcome Inc., the entity that manufactured and marketed Lo-tronox at all times material to Plaintiffs’ Complaint, and never marketed, promoted, or distributed Lotronex.” Id. at ¶ 2, dated July 15, 2003. 6

To date, Plaintiffs have only contradicted these affidavits with conclusory statements contained in their Complaint and Motion to Remand. They have submitted no evidence to contradict the affidavits. Cavallini v. State Farm Mut. Auto Ins. Co.,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cantor v. WACHOVIA MORTGAGE, FSB
641 F. Supp. 2d 602 (N.D. Texas, 2009)
Bourne v. Wal-Mart Stores, Inc.
582 F. Supp. 2d 828 (E.D. Texas, 2008)
Gaddis v. Smith & Nephew, Inc.
534 F. Supp. 2d 697 (S.D. Mississippi, 2008)
Rodriguez Ex Rel. Sifuentes v. Casa Chapa S.A., De C.V.
394 F. Supp. 2d 901 (W.D. Texas, 2005)
Jones v. Hartford Fire Insurance
347 F. Supp. 2d 328 (S.D. Mississippi, 2004)

Cite This Page — Counsel Stack

Bluebook (online)
338 F. Supp. 2d 704, 2004 U.S. Dist. LEXIS 20196, 2004 WL 2240998, Counsel Stack Legal Research, https://law.counselstack.com/opinion/randle-v-smithkline-beecham-corp-mssd-2004.